Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alphamab Oncology ( (HK:9966) ) has shared an announcement.
Alphamab Oncology has released additional information regarding its 2024 Annual Report, focusing on the utilization of treasury shares, proceeds from its Global Offering and Top-up Placing, and its Post-IPO Share Award Scheme. The company has yet to decide on the use of its treasury shares, while significant proceeds remain allocated for the development and commercialization of its key drug candidates KN046 and KN026. Additionally, funds from the Top-up Placing are primarily directed towards clinical trials and development of other drug candidates. The announcement clarifies that the Post-IPO Share Award Scheme does not require further disclosure under the Listing Rules, and the new information does not alter the previously disclosed details in the annual report.
The most recent analyst rating on (HK:9966) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
More about Alphamab Oncology
Alphamab Oncology is a biotechnology company focused on the research, development, and commercialization of innovative cancer therapies. The company is engaged in the development of key drug programs aimed at treating various forms of cancer, with a particular emphasis on the R&D and commercialization of its drug candidates KN046 and KN026.
Average Trading Volume: 4,256,836
Technical Sentiment Signal: Buy
Current Market Cap: HK$12.72B
See more data about 9966 stock on TipRanks’ Stock Analysis page.